Guardion® Receives approval from USPTO for expanded claims for its Proprietary Medical Device, the MAPCAT SF
October 23, 2019 07:00 ET
|
Guardion Health Sciences, Inc.
San Diego, California, Oct. 23, 2019 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (Nasdaq: GHSI) announced that it has received approval from the USPTO for...
Guardion Health Sciences Reports June 30, 2019 Interim Results of Operations
August 12, 2019 08:40 ET
|
Guardion Health Sciences, Inc.
Highlights Include: 18.2% Revenue Growth for the Three Months Ended June 30, 2019 and 21.7% Revenue Growth for the Six Months Ended June 30, 2019 San Diego, CA , Aug. 12, 2019 (GLOBE...
Guardion’s Proprietary Medical Device, the MapcatSF®, Receives Patent from the European Union
June 20, 2019 07:00 ET
|
Guardion Health Sciences, Inc.
San Diego, CA, June 20, 2019 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (Nasdaq: GHSI), an ocular health sciences and technologies company that develops,...
Guardion Health Sciences, Inc. Receives Official Trademark Registrations in China
May 01, 2019 07:00 ET
|
Guardion Health Sciences, Inc.
Guardion’s Lumega-Z product and MapcatSF device are key components of its two-pronged evidence-based protocol for the treatment of a depleted macular protective pigment, a known risk factor for...